FORA Capital LLC Has $144,000 Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

FORA Capital LLC decreased its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 78.7% during the 1st quarter, Holdings Channel.com reports. The fund owned 2,334 shares of the company’s stock after selling 8,626 shares during the quarter. FORA Capital LLC’s holdings in BridgeBio Pharma were worth $144,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Los Angeles Capital Management LLC boosted its holdings in BridgeBio Pharma by 1.7% in the first quarter. Los Angeles Capital Management LLC now owns 13,275 shares of the company’s stock valued at $818,000 after acquiring an additional 217 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in BridgeBio Pharma by 6.9% in the first quarter. Nisa Investment Advisors LLC now owns 6,211 shares of the company’s stock valued at $383,000 after acquiring an additional 400 shares during the last quarter. Penserra Capital Management LLC boosted its holdings in BridgeBio Pharma by 19.1% in the first quarter. Penserra Capital Management LLC now owns 3,365 shares of the company’s stock valued at $207,000 after acquiring an additional 540 shares during the last quarter. Parallel Advisors LLC bought a new position in BridgeBio Pharma in the first quarter valued at about $64,000. Finally, Exane Derivatives boosted its holdings in BridgeBio Pharma by 230.9% in the first quarter. Exane Derivatives now owns 1,638 shares of the company’s stock valued at $101,000 after acquiring an additional 1,143 shares during the last quarter. Institutional investors and hedge funds own 93.87% of the company’s stock.

Several equities analysts recently issued reports on BBIO shares. SVB Leerink reiterated a “buy” rating on shares of BridgeBio Pharma in a report on Sunday, April 11th. The Goldman Sachs Group reduced their target price on BridgeBio Pharma from $92.00 to $80.00 and set a “buy” rating on the stock in a report on Friday, May 7th. UBS Group assumed coverage on BridgeBio Pharma in a report on Thursday, May 20th. They set a “buy” rating and a $80.00 target price on the stock. Finally, Zacks Investment Research upgraded BridgeBio Pharma from a “sell” rating to a “hold” rating in a report on Tuesday, July 13th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $76.50.

NASDAQ BBIO opened at $61.60 on Thursday. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 4.48. The stock’s 50-day simple moving average is $60.19. BridgeBio Pharma, Inc. has a one year low of $26.17 and a one year high of $73.50.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Thursday, May 6th. The company reported ($1.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.35). The firm had revenue of $0.46 million during the quarter, compared to the consensus estimate of $21.91 million. Research analysts anticipate that BridgeBio Pharma, Inc. will post -3.96 earnings per share for the current fiscal year.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1.

Featured Article: volatile stocks

Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIO).

Institutional Ownership by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.